Risk factor
Fair trading liquidity
Profitability factor
Decent dividends
About
Established in 2008 and headquartered in Shenzhen, China, Shenzhen Lifotronic Technology Co., Ltd. specializes in the design, production, and distribution of a wide range of medical devices throughout China, addressing both diagnostic and therapeutic requirements. Its extensive portfolio includes In Vitro Diagnostic (IVD) products, featuring sophisticated analytical instruments such as HPLC systems for hemoglobin and HbA1c measurements, automated ECL immunoassay analyzers, and hematology analyzers. The company also provides Point-of-Care Testing (POCT) solutions, including immunofluorescence analyzers, alongside molecular diagnostics equipment like automated nucleic acid purification systems and real-time PCR platforms. Additionally, Lifotronic offers rapid test kits for key infectious diseases such as COVID-19, malaria, dengue, and influenza A and B. In the therapeutic sector, the company delivers a diverse array of solutions. Respiratory and ICU products encompass video laryngoscopes, warmer units with disposable blankets, high-flow humidification systems, high-frequency chest wall oscillation devices, and intermittent pneumatic compression pumps. For wound care, offerings include negative pressure wound therapy, ultrasound-assisted wound debridement, and wound healing light therapy. Pain management is addressed through ESWT (Extracorporeal Shockwave Therapy) devices, specifically electromagnetic and extracorporeal shockwave systems. Furthermore, Lifotronic is active in medical and aesthetic laser technologies, providing intensive pulsed light systems, fractional CO2 laser systems, Q-switched Nd:YAG laser systems, and fiber laser hair removal systems.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair value on
Target Price
The average target price of 688389.SS is 13.6 and suggests 20.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to